Search
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalThe FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications
Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsProducts: Eskelan 25 mg/ml-Injektions-/Infusionslösung in Ampullen, Eskelan 25 mg/ml-Injektionslösung in DurchstechflaschenFexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigationalFexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. … [L4269] It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation
Products: Good Neighbor Pharmacy Allergy ReliefRetapamulin
go.drugbank.com/drugs/DB01256ApprovedRetapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
Nesiritide
go.drugbank.com/drugs/DB04899ApprovedInvestigationalWithdrawnNesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic p...
Categories: Vasodilators Used in Cardiac DiseasesTuroctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalThis modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].
Tagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigationala myeloid malignancy in the dendritic cell lineage. … [A253762] It was also approved by the European Commission on January 7, 2021.[L43712]
Metreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigationalin food intake. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized
Synonyms: N-MethionylleptinmRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigationalmRNA-1283 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant lineage JN.1. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalThe hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875]. … Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S..
Methylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalFDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.